Meta-analysis of intravenous immunoglobulin preparation Octagam 10%® clinical effectiveness and safety

Polyclonal intravenous immunoglobulin G (IVIG) has been used for 50 years and has become a gold standard for treatment of primary and secondary immunodeficiencies, immune thrombocytopenia and others IVIG preparations are not identical. We performed a metanalysis of clinical trials of Octagam 10%® (Octapharma Pharmazeutika Prod.Ges.m.b.H., Vienna, Austria). Metanalysis demonstrated IVIG to be effective in reducing number of infections in primary and secondary immunodeficiencies, good clinical and laboratory response in immune thrombocytopenia, and also effectiveness in such conditions as Guillen-Barre syndrome, multifocal motor polyneuropathy, Myasthenia gravis, multiple sclerosis, dermatomyositis, polymyositis and others. The number of adverse infusion-related reactions were not different from average for this group of preparations even with highest infusion speed. In conclusion registered in Russia IVIG preparation Octagam 10%® demonstrated to be safe and effective.